MCF-7, an estrogenic receptor-positive (ER+) breast cancer line, provides insights into hormone-sensitive therapies [2], while MDA-MB-231, a triple-negative breast cancer model, is crucial for addressing aggressive and drug-resistant tumors [3]. Here, ESR1 is linked to triple-negative breast carcinoma.